Urigen Pharmaceuticals, Inc.
27 Maiden Lane, Suite 595, San Francisco, CA 94108
415 781-0350 www.urigen.com

Safe Harbor Statement Under the Private Securities Litigation Act of 1995 -- With the exception of historical information, the matters discussed herein are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Urigen could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. As with any new pharmaceutical product, there are significant risks in development, regulatory approval and commercialization of Urigen’s products. There are no guarantees that future clinical studies will confirm the preliminary results discussed in this document or that URG101 or URG301or any other Urigen product will receive regulatory approval for any medical condition. Further, even if Urigen were to receive regulatory approval for a product, there can be no assurance that such a product would prove to be commercially successful.
In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors see the risk factors associated with our Company, please review our SEC filings.

 Inventor of URG101
 Inventor of Elmiron ®
 #1 in license revenue for UCSD
 Sole Inventor on patent
 The standard of care
 About 250 publications
 Over 30 years of PBS/IC research
 Former Chair of Urology at UCSD, Currently Full Professor
 Residency at Penn and Scientific Training at the NIH
 M.D., Yale University School of Medicine

 Clinical-stage urology products
 No new chemical entity (NCE) risk
 Substantial markets for unmet medical needs
 URG101 - Painful Bladder
Syndrome/Interstitial Cystitis
 URG301 - Urethritis, Nocturia
 Experienced team
 Strong and expanding IP
URG101 –
Painful Bladder
URG301 – Urethritis

Painful Bladder Syndrome/Interstitial Cystitis
1 . Urine Contains Toxins, Electrolytes (Including K + )
Can damage exposed urothelium & activate nerves
2. Mucin Protects Urothelium
Loss of sulfated polysaccharide mucin layer results in damage to urothelium and loss of protection to bladder detrusor and nerves
3. Muscle Tissue
– Effects Urination
Detrusor muscle spasms. Frequent urination
4. Sensory Neurons – Monitor Bladder Status
Pain, urinary urgency and muscle spasms occur via electrolytes and toxins
Urigen Pharmaceuticals, Inc.
5

 PBS/IC often misdiagnosed as other disorders e.g. OAB, UTIs, endometriosis, prostatitis
 Overactive Bladder (OAB) - US Market ~17-33M
 Urinary Tract Infections (UTI) - 8M visits annually
 Endometriosis – US Women ~5.5M
 Significant Growth Prospects in an Underserved Market
*Wu et al.,(2006) A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis

Allergan AGN203818
NIDDK/Roche Cellcept
®
MediciNova MN001
Astellas IPD1151D
Pfizer PF04383119
Pfizer PD0299685
Plethora PSD597
Suspended in Phase II
Terminated
Suspended in Phase II/III
Phase II US & EU
Phase II US – injectable anti-NGF Ab
Phase II US – oral (pregabalin)
Phase II US – instilled anesthetic only
Urigen Pharmaceuticals, Inc.

 Lidocaine and heparin
 Product Advantages
 Rapid Pain Relief
 Easily assimilated into office practice
 Existing CPT Reimbursement
Code
 Generation of significant extra income for Urologists and Gynecologists

 URG101 Double blind, placebo-controlled Phase II Study in
Painful Bladder Syndrome/Interstitial Cystitis
 All End Points hit statistical significance
 Key Patent Issued 2008 (US Patent Protection to 2026)
 Extensive Safety Data
 Existing CPT Reimbursement Code

 Life Science Strategy Group surveyed urologists and payors
 Urologists “Very Likely” to prescribe URG101 for:
 PBS/IC Flares
 “Diagnostic” – Determines that Pain is from Bladder with first treatment
 Rapid adoption of URG101 expected within 7 months
 Payors Interviewed view URG101 favorably and will reimburse 100%

Normal Bladder PBS/IC Bladder with visible damage
 Bladder Pain with Urgency &
Frequency
 Urine leaks through bladder wall triggering pain & urgency
 No marketed product available for breakthrough symptoms
 ~10.5M US & Canada
 PBS/IC Market Poised For Growth
 ’09 RAND Interstitial Cystitis Epidemiology study prevalence ~3-8M US women with IC
 <50,000 Elmiron ® scripts, but growing

Last drug approved in 1997
URG101 Comparison to Market Leader
Elmiron
®
(J&J)
 3-6 Months for Effect
 Three times per day
 Oral capsules
 Artificial heparinoid
URG101



Effect within Minutes
Two/three per Flare
Instillation (MD Revenue)
 Heparin-lidocaine formulation

URG101 for Painful Bladder Syndrome
 Completed Positive Phase II study
 Filed for FDA Meeting on April 22, 2010
 ~$10M - $12M cost to NDA filing
 Existing reimbursement code (CPT)
 Peak sales est. $500M*
 US Patent protection to 2026
*
Life Science Strategy Group

URG101-104

% Change in Pain over Time
0
-10
-20
50%
-30
-40
11%
-50
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (hours) n = 18
Urigen Pharmaceuticals, Inc.
15

Endpoint
Primary Endpoint
Symptom P Value
% Improvement Ave Daytime Pain
Secondary Endpoints
PORIS Question 3 (0.5hr)
% Improvement Ave Daytime Urge
% Improvement Ave Total Symptom
Score
Pain 0.036
Pain/Urgency 0.014
Urgency 0.033
Pain/Urgency 0.032


 Many patients experienced > 24hr symptom relief following only one dose.
 Significant reduction of daytime symptoms
 Many patients experienced fewer night time voiding episodes.

1. Patent licensed from UCSD
 U.S. Patent 7,414,039 covering the use of the composition of a local anesthetic, heparinoid and buffer for the treatment of symptoms of interstitial cystitis
 Coverage to 2026
2. Urigen patent application
 Improved compositions for treatments
 Pending in US, EU, other jurisdictions

URG301: buffered lidocaine urethral suppository
 Occupies ~ 65% of the female urethra
 Melts promptly upon insertion
 Distributes the drug to the urethral and bladder tissues
 Achieves rapid anesthetic effect
 Calms pain and urgency
 Two issued patents
URG301
Urigen Pharmaceuticals, Inc.
19

 Unsatisfied Market
 Afflicts at least 16 million American women*
 Under-reported, under-treated
 4 million ‘drop outs’ in 2006: 90% at 11 months**
 Characterized By:
 Relentless urge and frequency to ‘go’
 Reduced social mobility/sleep interruption
 Current Medications
 Reduce frequency by ‘one’ event in 24 hours
 Significant frequency of bothersome side effects
 None provide sleep or social relief
*Mayo Clin Proc 2001; 76:358-363; **IMS 2006 Prescription Data
Urigen Pharmaceuticals, Inc.
20



 Healthy Volunteers
 Pain scale endpoints
Urigen Pharmaceuticals, Inc.
21

 C. Lowell Parsons, MD – Inventor of URG101 & Elmiron ®
($170M Urology Drug)
 Michael M. Goldberg, MD – Platinum-Montaur Life Sciences,
LLC
 William J. Garner, MD – President & CEO
 Martin E. Shmagin – Chief Financial Officer
 Edward R. Teitel, MD,JD,MBA – CEO, ThromboVision, Inc.
 Dan B. Vickery, Ph.D. – President, BioEnsemble, Ltd.
 Robert J. Watkins, RJ Watkins & Company – ex-J&J

$450,000,000
$400,000,000
$350,000,000
$300,000,000
Gynecologists
Urologists
$250,000,000
$200,000,000
$150,000,000
$100,000,000
$50,000,000
$0
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7
Gynecologists $74,846,247 $129,933,666 $181,207,059 $233,056,318 $281,274,121 $355,551,551 $425,980,304
Urologists $28,523,398 $42,211,465 $54,830,598 $67,465,033 $79,035,930 $98,468,800 $117,004,847
Urigen Pharmaceuticals, Inc.
Source: Physician interviews; Navigant Consulting, Inc. 2006

OTC BB: URGP
 151,535 Average Daily Volume
 $0.19 52 week high


$0.05 52 week low
$12.96M Market Cap





*88,733,194 common shares outstanding
210 convertible preferred shares outstanding that convert to 21,000,000 common shares
17,260,790 warrants that convert at $0.125
5,524,410 convertible preferred shares outstanding that convert to
5,529,410
33.19% Insider ownership
*Includes 2.5M to be issued
Urigen Pharmaceuticals, Inc.

 URG101 FDA meeting filed April 22, 2010 (Phase
II met all endpoints)
 Strengthen Balance Sheet For Tier 1 Partnerships
 URG301 Phase I Tolerability Study

Urigen Pharmaceuticals, Inc.
27 Maiden Lane, #595, San Francisco, CA 94108
(415) 781-0350 www.urigen.com
26